US 12,410,483 B2
Methods of detecting bladder cancer
Russell Higuchi, Alameda, CA (US); Stacey Ellen Wallace, Sunnyvale, CA (US); and Edwin Wei-Lung Lai, Menlo Park, CA (US)
Assigned to Cepheid, Sunnyvale, CA (US)
Filed by Cepheid, Sunnyvale, CA (US)
Filed on Oct. 12, 2023, as Appl. No. 18/485,615.
Application 16/272,978 is a division of application No. 14/394,352, granted, now 10,202,653, issued on Feb. 12, 2019, previously published as PCT/US2013/037334, filed on Apr. 19, 2013.
Application 18/485,615 is a continuation of application No. 16/272,978, filed on Feb. 11, 2019, abandoned.
Claims priority of provisional application 61/770,803, filed on Feb. 28, 2013.
Claims priority of provisional application 61/636,194, filed on Apr. 20, 2012.
Prior Publication US 2024/0175089 A1, May 30, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); C12Q 2600/166 (2013.01)] 21 Claims
 
1. A method for detecting bladder cancer markers in a subject comprising detecting the levels of each bladder cancer marker amplicon of a set of bladder cancer markers in a urine sample or bladder washing sample from the subject, wherein the set of bladder cancer markers consists of corticotrophin releasing hormone (CRH), insulin-like growth factor 2 (IGF2), keratin 20 (KRT20) and annexin 10 (ANXA10), by contacting RNA from the sample with a set of primers, conducting one or more polymerase chain reactions (PCR) and detecting a set of bladder cancer marker amplicons that is produced by the PCR.